391 related articles for article (PubMed ID: 34899738)
1. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
Rayasam A; Drobyski WR
Front Immunol; 2021; 12():779076. PubMed ID: 34899738
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease.
Piper C; Drobyski WR
Front Immunol; 2019; 10():163. PubMed ID: 30853956
[TBL] [Abstract][Full Text] [Related]
3. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging strategies for the prevention of graft-versus-host disease.
Choi SW; Reddy P
Nat Rev Clin Oncol; 2014 Sep; 11(9):536-47. PubMed ID: 24958183
[TBL] [Abstract][Full Text] [Related]
5. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
Front Immunol; 2021; 12():757836. PubMed ID: 34712243
[TBL] [Abstract][Full Text] [Related]
6. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.
Hill GR; Ferrara JL
Blood; 2000 May; 95(9):2754-9. PubMed ID: 10779417
[TBL] [Abstract][Full Text] [Related]
7. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
9. Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease.
Kim S; Reddy P
Front Immunol; 2020; 11():722. PubMed ID: 32411139
[TBL] [Abstract][Full Text] [Related]
10. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Tsubokura Y; Yoshimura H; Satake A; Nasa Y; Tsuji R; Ito T; Nomura S
Immun Inflamm Dis; 2022 Sep; 10(9):e688. PubMed ID: 36039651
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid-responsive CD8 effector T cells are selectively increased in IL-23-rich tissue in gastrointestinal GVHD.
Ball JA; Clear A; Aries J; Charrot S; Besley C; Mee M; Stagg A; Lindsay JO; Cavenagh J; Calaminci M; Gribben JG; Davies J
Blood; 2021 Feb; 137(5):702-717. PubMed ID: 32905596
[TBL] [Abstract][Full Text] [Related]
12. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
[TBL] [Abstract][Full Text] [Related]
13. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.
Sheng-Tanner X; McKerlie C; Spaner D
Transplantation; 2000 Dec; 70(12):1683-93. PubMed ID: 11152097
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
Carnevale-Schianca F; Leisenring W; Martin PJ; Furlong T; Schoch G; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Kiem HP; Storb R; McDonald GB; Nash RA
Biol Blood Marrow Transplant; 2009 Jun; 15(6):749-56. PubMed ID: 19450760
[TBL] [Abstract][Full Text] [Related]
15. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
16. GVHD Prophylaxis 2020.
Gooptu M; Antin JH
Front Immunol; 2021; 12():605726. PubMed ID: 33897681
[TBL] [Abstract][Full Text] [Related]
17. Intestinal graft-versus-host disease: mechanisms and management.
Takatsuka H; Iwasaki T; Okamoto T; Kakishita E
Drugs; 2003; 63(1):1-15. PubMed ID: 12487619
[TBL] [Abstract][Full Text] [Related]
18. The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.
Newman RG; Ross DB; Barreras H; Herretes S; Podack ER; Komanduri KV; Perez VL; Levy RB
Immunol Res; 2013 Dec; 57(1-3):125-39. PubMed ID: 24272856
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
